Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film

January 2, 2020— Sunovion Pharmaceuticals, Inc. issued a press release announcing that its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) has been accepted by the U.S. Food and Drug Administration. This on-demand treatment is being developed for ALL types of OFF episodes. The expected action date by the FDA is May 21, 2020.
Read More,